Next Article in Journal
Biochemical Pathways Leading to the Formation of Wyosine Derivatives in tRNA of Archaea
Previous Article in Journal
Recent Development of Aminoacyl-tRNA Synthetase Inhibitors for Human Diseases: A Future Perspective
 
 
Article

New Trends for Antimalarial Drugs: Synergism between Antineoplastics and Antimalarials on Breast Cancer Cells

by 1,2 and 1,3,*
1
OncoPharma Research Group, Center for Health Technology and Services Research (CINTESIS), Rua Plácido da Costa, 4200-450 Porto, Portugal
2
Faculty of Pharmacy, University of Porto, Rua Jorge Viterbo Ferreira, 228, 4050-313 Porto, Portugal
3
Faculty of Medicine, University of Porto, Al. Hernâni Monteiro, 4200-319 Porto, Portugal
*
Author to whom correspondence should be addressed.
Biomolecules 2020, 10(12), 1623; https://doi.org/10.3390/biom10121623
Received: 19 November 2020 / Revised: 28 November 2020 / Accepted: 29 November 2020 / Published: 1 December 2020
(This article belongs to the Section Molecular Medicine)
Chemotherapy plays a key role in breast cancer therapy, but drug resistance and unwanted side effects make the treatment less effective. We propose a new combination model that combines antineoplastic drugs and antimalarials for breast cancer therapy. Cytotoxic effects of two antineoplastic agents alone and in combination with several antimalarials on MCF-7 tumor cell line was evaluated. Different concentrations in a fixed ratio were added to the cultured cells and incubated for 48 h. Cell viability was evaluated using MTT and SRB assays. Synergism was evaluated using the Chou-Talalay method. The results indicate doxorubicin (DOX) and paclitaxel (PTX) alone at concentrations of their IC50 and higher are cell growth inhibitors. Mefloquine, artesunate, and chloroquine at concentrations of their IC50 demonstrate anti-cancer activity. In combination, almost all antimalarials demonstrate higher ability than DOX and PTX alone to decrease cell viability at concentrations of IC50 and lower than their IC50. The combination of chloroquine, artesunate and mefloquine with DOX and PTX was synergic (CI < 1). The combination of DOX and mefloquine after 48 h incubation demonstrated the highest cytotoxicity against MCF-7 cells, and the combination of DOX and artesunate was the most synergic. These results suggest antimalarials could act synergistically with DOX/PTX for breast cancer therapy. View Full-Text
Keywords: breast cancer; drug synergism; antineoplastic drugs; drug repurposing; antimalarial drugs; combination therapy breast cancer; drug synergism; antineoplastic drugs; drug repurposing; antimalarial drugs; combination therapy
Show Figures

Graphical abstract

MDPI and ACS Style

Duarte, D.; Vale, N. New Trends for Antimalarial Drugs: Synergism between Antineoplastics and Antimalarials on Breast Cancer Cells. Biomolecules 2020, 10, 1623. https://doi.org/10.3390/biom10121623

AMA Style

Duarte D, Vale N. New Trends for Antimalarial Drugs: Synergism between Antineoplastics and Antimalarials on Breast Cancer Cells. Biomolecules. 2020; 10(12):1623. https://doi.org/10.3390/biom10121623

Chicago/Turabian Style

Duarte, Diana, and Nuno Vale. 2020. "New Trends for Antimalarial Drugs: Synergism between Antineoplastics and Antimalarials on Breast Cancer Cells" Biomolecules 10, no. 12: 1623. https://doi.org/10.3390/biom10121623

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop